Tengshengbo's new coronary pneumonia neutralizing antibody combination therapy phase III study is completed and enrolled

On August 5, Tengshengbo Pharmaceutical announced that its monoclonal neutralizing antibody BRII-196/BRII-198 combination therapy phase III ACTIV-2 study has completed 846 subjects in research centers in the United States, Brazil, South Africa, Mexico and Argentina Join the group

The ACTIV-2 study was funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health (NIH).

After the study is completed, the ACTIV-2 data set will be analyzed, including patients enrolled in the group during the rapid emergence of the global new severe acute respiratory syndrome virus 2 (SARS-CoV-2) variant from January to July 2021

The current Phase I and Phase II clinical trial data show that the BRII-196/BRII-198 combination therapy has good safety and tolerability

About the ACTIV-2 study

The ACTIV-2 trial (NCT04518410) was funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health (NIH) and sponsored by the AIDS Clinical Trial Group (ACTG) funded by NIAID

The ACTIV-2 main program adopts a randomized, double-blind, and controlled adaptive platform clinical trial design to evaluate the safety and effectiveness of therapeutic drugs for symptomatic non-hospital adult patients with new coronary disease

About BRII-196 and BRII-198

BRII-196 and BRII-198 are non-competitive new severe acute respiratory syndrome virus 2 (SARS-CoV-2) monoclonal neutralizing antibodies obtained from patients with new coronavirus pneumonia (COVID-19) during the convalescence period.

New drug clinical trial applications for the BRII-196/BRII-198 combination therapy have been submitted to the U.